Duchenne Muscular Dystrophy: Pipeline And Partnering Snapshot
A full pipeline of symptomatic and disease-modifying treatments for Duchenne will transform a long dormant orphan market into a hotly contested commercial prize. But some issues, foremost the scarcity of trial patients, threaten to stall progress in the field.
You may also be interested in...
Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.
The race to get a Duchenne muscular dystrophy drug to market has been closely watched by investors; new developments in drugs by Prosensa and Sarepta have created an unexpected change in the landscape of treatment development.
The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.